Image source: Getty
Continue Reading Below
What:Shareholders ofRigel Pharmaceuticals(NASDAQ: RIGL), a small-cap clinical stage biopharma, are having a pleasant Tuesday. The company's stock is soaring, up more than 36% as of 11:15 a.m. EDT after management released encouraging data fromRigel's first FIT phase 3 clinical trial.
So what: The trial was designed to measure Fostamatinib's, the company's lead compound, ability toraise blood platelet levels in adult patients with primary chronic immune thrombocytopenia, or ITP. This disease causes a patient's own immune system to seek out and destroy blood platelets, which are critical for healing and clotting.
The study showed that 18% of patients who used Fostamatinib were able to achieve a stable platelet response, whichwas defined as 50,000 platelets per uL of blood on at least four of the last six scheduled clinic visits. That result compared favorably to the 0% response rate observed in the control group and was shown to be statistically significant. In addition, thesafety profile of the compound was consistent with prior clinical experience.
The patients whomet the study's primary endpoint platelet counts, an increase from a median starting point of 16,000/uL to a median over 100,000/uL at week 24, have all since enrolled in the long-term phase 3 extension study and have maintained elevated platelet levels beyond the initial 24 week study period.
Given the good clinical news all around it's easy to understand why shares are popping.
Now what:Results from Rigel's second FIT phase 3 study are expected to be released in October or November of this year. If these sameresults are reproduced in that study as well as during an interim look at the on-going phase 3 extension study, then Rigel plans on submitting Fostamatinib for regulatory reviewin the first quarter of 2017.
There are approximately 50,000 to 60,000 adult patients in the U.S. who are living with primary chronic ITP. That's a relatively small patient population, so the FDA has already decided to give Fostamatinib Orphan drug status. That should allow Rigel to charge a huge premium if the drug can find its way to market, which is why some analysts foresee peak sales running above $350 million. That's a lot of money when compared to Rigel's current market cap of only $340 million.
While I understand the market's optimism given the clinical result, Rigel still has plenty of work ahead of it beforeFostamatinib can start to actually produce revenue. For that reason potential investors might want to wait until the second round of FIT data is available later this year before they consider jumping in.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.